Comparative Pharmacology
Head-to-head clinical analysis: BACTOCILL versus PENTIDS 250.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACTOCILL versus PENTIDS 250.
BACTOCILL vs PENTIDS '250'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BACTOCILL (nafcillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibitors. Active against Staphylococcus aureus and other gram-positive bacteria.
Penicillin G binds to penicillin-binding proteins (PBPs) located on the bacterial cell wall, inhibiting transpeptidase activity and cell wall synthesis, leading to bacterial lysis.
250-500 mg orally every 6 hours or 1-2 g intravenously every 4-6 hours
250 mg orally every 8 hours.
None Documented
None Documented
0.5-0.8 hours; prolonged to 2-4 hours in severe renal impairment
0.5-1 hour (prolonged in renal impairment; requires dose adjustment when CrCl <30 mL/min)
Renal: 60-70% unchanged; biliary: 20-30% as active metabolite; fecal: 5-10%
Primarily renal (60-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal (10-30%)
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic